CanaQuest Medical Corp
OTC:CANQF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CanaQuest Medical Corp
OTC:CANQF
|
CA |
|
Blackwall Ltd
ASX:BWF
|
AU |
|
M
|
Miluna Acquisition Corp
NASDAQ:MMTX
|
TW |
|
S
|
Salona Cotspin Ltd
NSE:SALONA
|
IN |
|
S
|
Sekonix Co Ltd
KOSDAQ:053450
|
KR |
|
E
|
Earth Life Sciences Inc
OTC:CLTS
|
CA |
|
C
|
China Marine Food Group Ltd
OTC:CMFO
|
CN |
|
G
|
General Environmental Management Inc
OTC:GEVI
|
US |
|
Kore Mining Ltd
XTSX:KORE
|
CA |
|
R
|
Rio Silver Inc
XTSX:RYO
|
CA |
|
P
|
Phoenix Education Partners Inc
NYSE:PXED
|
US |
|
BFF Bank SpA
OTC:BFFBF
|
IT |
|
I
|
IC Capitalight Corp
CNSX:IC
|
CA |
|
FST Ltd
NASDAQ:KBSX
|
SG |
|
Nickelsearch Ltd
ASX:NIS
|
AU |
|
A
|
Alchemy Investments Acquisition Corp 1
NASDAQ:ALCY
|
US |
CanaQuest Medical Corp
CanaQuest Medical Corp. is a pharmaceutical company, which is focused on the medical cannabis products, utilizing cannabinoid molecules, and other botanical compounds. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-10-27. The firm has developed two commercial-ready Master Formulations, Mentanine and Mentabinol, which are for treating mental health ailments. The company has also identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the United States for epilepsy rare diseases. The firm has the modified Mentanine formulation in combination with its processing and delivery method, which is for epilepsy treatment as a Rx drug. The firm is selling both products to patients through its wholly owned subsidiary, ADC BioMedical Corp.
CanaQuest Medical Corp. is a pharmaceutical company, which is focused on the medical cannabis products, utilizing cannabinoid molecules, and other botanical compounds. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-10-27. The firm has developed two commercial-ready Master Formulations, Mentanine and Mentabinol, which are for treating mental health ailments. The company has also identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the United States for epilepsy rare diseases. The firm has the modified Mentanine formulation in combination with its processing and delivery method, which is for epilepsy treatment as a Rx drug. The firm is selling both products to patients through its wholly owned subsidiary, ADC BioMedical Corp.
